Stojanovski Bosko M, Ferreira Gloria C
From the Department of Molecular Medicine, Morsani College of Medicine, and.
From the Department of Molecular Medicine, Morsani College of Medicine, and the Department of Chemistry, University of South Florida, Tampa, Florida 33612
J Biol Chem. 2015 Dec 25;290(52):30750-61. doi: 10.1074/jbc.M115.655399. Epub 2015 Oct 28.
5-Aminolevulinate synthase (ALAS) catalyzes the first step in mammalian heme biosynthesis, the pyridoxal 5'-phosphate (PLP)-dependent and reversible reaction between glycine and succinyl-CoA to generate CoA, CO2, and 5-aminolevulinate (ALA). Apart from coordinating the positioning of succinyl-CoA, Rhodobacter capsulatus ALAS Asn-85 has a proposed role in regulating the opening of an active site channel. Here, we constructed a library of murine erythroid ALAS variants with substitutions at the position occupied by the analogous bacterial asparagine, screened for ALAS function, and characterized the catalytic properties of the N150H and N150F variants. Quinonoid intermediate formation occurred with a significantly reduced rate for either the N150H- or N150F-catalyzed condensation of glycine with succinyl-CoA during a single turnover. The introduced mutations caused modifications in the ALAS active site such that the resulting variants tipped the balance between the forward- and reverse-catalyzed reactions. Although wild-type ALAS catalyzes the conversion of ALA into the quinonoid intermediate at a rate 6.3-fold slower than the formation of the same quinonoid intermediate from glycine and succinyl-CoA, the N150F variant catalyzes the forward reaction at a mere 1.2-fold faster rate than that of the reverse reaction, and the N150H variant reverses the rate values with a 1.7-fold faster rate for the reverse reaction than that for the forward reaction. We conclude that the evolutionary selection of Asn-150 was significant for optimizing the forward enzymatic reaction at the expense of the reverse, thus ensuring that ALA is predominantly available for heme biosynthesis.
5-氨基乙酰丙酸合酶(ALAS)催化哺乳动物血红素生物合成的第一步,即吡哆醛5'-磷酸(PLP)依赖性且可逆的甘氨酸与琥珀酰辅酶A之间的反应,生成辅酶A、二氧化碳和5-氨基乙酰丙酸(ALA)。除了协调琥珀酰辅酶A的定位外,荚膜红细菌ALAS的天冬酰胺-85在调节活性位点通道的开放方面具有推测的作用。在此,我们构建了一个小鼠红系ALAS变体文库,这些变体在与细菌类似天冬酰胺占据的位置上有替代,筛选其ALAS功能,并对N150H和N150F变体的催化特性进行了表征。在单次周转期间,对于N150H或N150F催化的甘氨酸与琥珀酰辅酶A的缩合反应,醌类中间体的形成速率显著降低。引入的突变导致ALAS活性位点发生修饰,使得产生的变体改变了正向和反向催化反应之间的平衡。虽然野生型ALAS催化ALA转化为醌类中间体的速率比由甘氨酸和琥珀酰辅酶A形成相同醌类中间体的速率慢6.3倍,但N150F变体催化正向反应的速率仅比反向反应快1.2倍,而N150H变体则使速率值反转,反向反应的速率比正向反应快1.7倍。我们得出结论,天冬酰胺-150的进化选择对于以牺牲反向反应为代价优化正向酶促反应具有重要意义,从而确保ALA主要可用于血红素生物合成。